Literature DB >> 17874276

Analysis of recurrence pattern and its influence on survival outcome after radiofrequency ablation of hepatocellular carcinoma.

Kelvin K Ng1, Ronnie T Poon, Chung-Mau Lo, Jimmy Yuen, Wai Kuen Tso, Sheung-Tat Fan.   

Abstract

BACKGROUND: Radiofrequency ablation (RFA) is an effective local ablation therapy for hepatocellular carcinoma (HCC) with favorable long-term outcome. There is no data on the analysis of recurrence pattern and its influence on long-term survival outcome after RFA in HCC patients.
AIM OF STUDY: To evaluate the tumor recurrence pattern and its influence on long-term survival in patients with HCC treated with RFA. PATIENTS AND METHODS: From April 2001 to January 2005, 209 patients received RFA using internally cooled electrode as the sole treatment modality for HCC. Among them, 117 patients (56%) had unresectable HCC because of bilobar disease, poor liver function, and/or high medical risk for resection; whereas 92 patients (44%) underwent RFA as the primary treatment for small resectable HCC. The ablation procedure was performed through percutaneous (n=101), laparoscopic (n=17), or open approaches (n=91). The tumor recurrence pattern and long-term survival were analyzed. Multivariate analysis was carried out to identify independent prognostic factors affecting the overall survival of patients.
RESULTS: The mortality and morbidity rates were 0.9 and 15.7%, respectively. Complete tumor ablation was achieved in 192 patients (92.7%). With a median follow-up period of 26 months, local recurrence occurred in 28 patients (14.5%). Same segment and different segment intrahepatic recurrence occurred in 30 patients (15.6%) and 78 patients (40.6%), respectively. Twenty patients (10.4%) developed distant extrahepatic metastases. The overall 1-, 3-, and 5-year survival rates were 87.2, 66.6, and 42%, respectively. Different segment intrahepatic recurrence and distant recurrence after RFA carried significant poor prognostic influence on overall survival outcome. Using multivariate analysis, Child-Pugh grade (risk ratio [RR]=2.918, 95% confident interval [CI] 1.704-4.998, p=0.000), tumor size (RR=1.231, 95% CI 1.031-1.469, p=0.021), and pattern of recurrence (risk ratio [RR]=1.464, 95% CI 1.156-1.987, P=0.020) were identified as independent prognostic factors for overall survival.
CONCLUSION: The tumor recurrence pattern after RFA carries significant prognostic value in relation to overall survival. Long-term regular surveillance and aggressive treatment strategy are required for patients with different segment intrahepatic recurrence to optimize the benefits of RFA.

Entities:  

Mesh:

Year:  2007        PMID: 17874276     DOI: 10.1007/s11605-007-0276-y

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  25 in total

1.  Liver anatomy: portal (and suprahepatic) or biliary segmentation.

Authors:  C Couinaud
Journal:  Dig Surg       Date:  1999       Impact factor: 2.588

2.  Percutaneous radiofrequency ablation for hepatocellular carcinoma. An analysis of 1000 cases.

Authors:  Ryosuke Tateishi; Shuichiro Shiina; Takuma Teratani; Shuntaro Obi; Shinpei Sato; Yukihiro Koike; Tomonori Fujishima; Haruhiko Yoshida; Takao Kawabe; Masao Omata
Journal:  Cancer       Date:  2005-03-15       Impact factor: 6.860

3.  Significant long-term survival after radiofrequency ablation of unresectable hepatocellular carcinoma in patients with cirrhosis.

Authors:  Chandrajit P Raut; Francesco Izzo; Paolo Marra; Lee M Ellis; Jean-Nicolas Vauthey; Francesco Cremona; Paolo Vallone; Angelo Mastro; Bruno D Fornage; Steven A Curley
Journal:  Ann Surg Oncol       Date:  2005-06-20       Impact factor: 5.344

4.  A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma.

Authors:  Shuichiro Shiina; Takuma Teratani; Shuntaro Obi; Shinpei Sato; Ryosuke Tateishi; Tomonori Fujishima; Takashi Ishikawa; Yukihiro Koike; Haruhiko Yoshida; Takao Kawabe; Masao Omata
Journal:  Gastroenterology       Date:  2005-07       Impact factor: 22.682

5.  An analysis of 412 cases of hepatocellular carcinoma at a Western center.

Authors:  Y Fong; R L Sun; W Jarnagin; L H Blumgart
Journal:  Ann Surg       Date:  1999-06       Impact factor: 12.969

6.  Long-term follow-up outcome of patients undergoing radiofrequency ablation for unresectable hepatocellular carcinoma.

Authors:  Junji Machi; Racquel S Bueno; Linda L Wong
Journal:  World J Surg       Date:  2005-11       Impact factor: 3.352

7.  Radiofrequency ablation of hepatocellular cancer in 110 patients with cirrhosis.

Authors:  S A Curley; F Izzo; L M Ellis; J Nicolas Vauthey; P Vallone
Journal:  Ann Surg       Date:  2000-09       Impact factor: 12.969

8.  Treatment of hepatocellular carcinoma using percutaneous radiofrequency thermoablation: results and outcomes in 56 patients.

Authors:  Marc Giovannini; Vincent Moutardier; Carcline Danisi; Erwan Bories; Christian Pesenti; Jean-Robert Delpéro
Journal:  J Gastrointest Surg       Date:  2003 Sep-Oct       Impact factor: 3.452

9.  Flow cytometric DNA analysis of cirrhotic liver cells in patients with hepatocellular carcinoma can provide a new prognostic factor.

Authors:  S Ruà; A Comino; A Fruttero; P Torchio; H Bouzari; S Taraglio; B Torchio; L Capussotti
Journal:  Cancer       Date:  1996-09-15       Impact factor: 6.860

10.  Small hepatocellular carcinoma in cirrhosis: randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection.

Authors:  Riccardo A Lencioni; Hans-Peter Allgaier; Dania Cioni; Manfred Olschewski; Peter Deibert; Laura Crocetti; Holger Frings; Joerg Laubenberger; Ina Zuber; Hubert E Blum; Carlo Bartolozzi
Journal:  Radiology       Date:  2003-05-20       Impact factor: 11.105

View more
  39 in total

1.  A special recurrent pattern in small hepatocellular carcinoma after treatment: bile duct tumor thrombus formation.

Authors:  Qing-Yu Liu; Dong-Ming Lai; Chao Liu; Lei Zhang; Wei-Dong Zhang; Hai-Gang Li; Ming Gao
Journal:  World J Gastroenterol       Date:  2011-11-21       Impact factor: 5.742

2.  Role for putative hepatocellular carcinoma stem cell subpopulations in biological response to incomplete thermal ablation: in vitro and in vivo pilot study.

Authors:  Scott M Thompson; Matthew R Callstrom; Kim A Butters; Shari L Sutor; Bruce Knudsen; Joseph P Grande; Lewis R Roberts; David A Woodrum
Journal:  Cardiovasc Intervent Radiol       Date:  2014-01-23       Impact factor: 2.740

3.  Hepatocellular carcinoma: clinical study of long-term survival and choice of treatment modalities.

Authors:  Ke-Tong Wu; Cun-Chuan Wang; Li-Gong Lu; Wei-Dong Zhang; Fu-Jun Zhang; Feng Shi; Chuan-Xing Li
Journal:  World J Gastroenterol       Date:  2013-06-21       Impact factor: 5.742

4.  Multi-disciplinary Concurrent Management of Recurrent Hepatocellular Therapy is Superior to Sequential Therapy.

Authors:  Tyler D Fields; Prejesh Philips; Charles R Scoggins; Cliff Tatum; Lawrence Kelly; Kelly M McMasters; Robert C G Martin
Journal:  World J Surg       Date:  2017-05       Impact factor: 3.352

Review 5.  Microwave tumor ablation: mechanism of action, clinical results, and devices.

Authors:  Meghan G Lubner; Christopher L Brace; J Louis Hinshaw; Fred T Lee
Journal:  J Vasc Interv Radiol       Date:  2010-08       Impact factor: 3.464

Review 6.  Microwave ablation of hepatic malignancy.

Authors:  Meghan G Lubner; Christopher L Brace; Tim J Ziemlewicz; J Louis Hinshaw; Fred T Lee
Journal:  Semin Intervent Radiol       Date:  2013-03       Impact factor: 1.513

7.  Survival analysis of high-intensity focused ultrasound ablation in patients with small hepatocellular carcinoma.

Authors:  Tan To Cheung; Sheung Tat Fan; Ferdinand S K Chu; Caroline R Jenkins; Kenneth S H Chok; Simon H Y Tsang; Wing Chiu Dai; Albert C Y Chan; See Ching Chan; Thomas C C Yau; Ronnie T P Poon; Chung Mau Lo
Journal:  HPB (Oxford)       Date:  2012-12-04       Impact factor: 3.647

8.  Ultrasound-guided percutaneous microwave ablation for hepatocellular carcinoma: clinical outcomes and prognostic factors.

Authors:  Sicong Ma; Min Ding; Jiang Li; Tao Wang; Xingxing Qi; Yaoping Shi; Yanan Ming; Jiachang Chi; Zhi Wang; Xiaoyin Tang; Dan Cui; Yuan Zhang; Bo Zhai
Journal:  J Cancer Res Clin Oncol       Date:  2016-09-20       Impact factor: 4.553

9.  18F-FDG-PET/CT predicts the distribution of microsatellite lesions in hepatocellular carcinoma.

Authors:  Hironori Ochi; Masashi Hirooka; Atsushi Hiraoka; Yohei Koizumi; Masanori Abe; Ichiro Sogabe; Yoshihiro Ishimaru; Keizou Furuya; Masao Miyagawa; Hideki Kawasaki; Kojiro Michitaka; Yasutsugu Takada; Teruhito Mochizuki; Yoichi Hiasa
Journal:  Mol Clin Oncol       Date:  2014-06-25

10.  Radiofrequency ablation combined with KS-IL2 immunocytokine (EMD 273066) results in an enhanced antitumor effect against murine colon adenocarcinoma.

Authors:  Erik E Johnson; Brett H Yamane; Ilia N Buhtoiarov; Hillary D Lum; Alexander L Rakhmilevich; David M Mahvi; Stephen D Gillies; Paul M Sondel
Journal:  Clin Cancer Res       Date:  2009-07-28       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.